All sponsors

Karyopharm Therapeutics Inc $KPTIQ

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-33
RECRUITING3
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO100%

Delay Index: of 6 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +27.7 months). See all sponsors →

Open Karyopharm Therapeutics Inc on the live radar map → 📅 $KPTIQ readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
SENTRY
NCT04562389
P3Active, not recruitingMyelofibrosis3532026-02-20 (+28 mo)
XPORT-EC-042
NCT05611931
P3Active, not recruitingEndometrial Cancer2572026-05-22 (+23 mo)
Selinexor
NCT04562870
P2Active, not recruitingMyelofibrosis1122026-09 (+39 mo)
Selinexor (combination therapy)
NCT04442022
P2/3Active, not recruitingRelapsed/Refractory Diffuse Large B-cell Lymphoma5012026-12 (+16 mo)
Selinexor
NCT02227251
P2Active, not recruitingDiffuse Large B-cell Lymphoma2442026-12
STOMP
NCT02343042
P1/2RecruitingMultiple Myeloma3002027-04
SENTRY-2
NCT05980806
P2RecruitingMyelofibrosis; Moderate Thrombocytopenia582027-06 (+14 mo)
Selinexor
NCT04414475
P2RecruitingMultiple Myeloma, Refractory1272028-01 (+59 mo)